Management of cutaneous leishmaniasis

Area of Science:

• Dermatology
• Infectious Diseases
• Parasitology

Background:

• Cutaneous leishmaniasis presents a significant global health challenge, demanding novel therapeutic strategies.
• Current treatment options for cutaneous leishmaniasis are limited in efficacy, safety, and accessibility.
• Diagnosis relies on clinical presentation and parasite detection, with molecular methods offering advancements.

Purpose of the Study:

• To review recent advancements in the diagnosis and treatment of cutaneous leishmaniasis.
• To assess the impact of new findings on current clinical management protocols.
• To highlight the ongoing need for improved therapeutic interventions.

Main Methods:

• Review of recent scientific literature and clinical studies on cutaneous leishmaniasis.
• Analysis of diagnostic methodologies, including traditional and molecular approaches.
• Evaluation of current and emerging treatment strategies.

Main Results:

• Despite recent contributions, no single new development has revolutionized cutaneous leishmaniasis management.
• Molecular diagnostic techniques, particularly those targeting kinetoplast DNA, are increasingly utilized for diagnosis and strain identification.
• Pentavalent antimonials continue to be the primary therapeutic agents for cutaneous leishmaniasis.

Conclusions:

• The search for an ideal cutaneous leishmaniasis treatment—safe, effective, easily administered, and inexpensive—persists.
• Advancements in molecular diagnostics enhance parasite identification and typing.
• Pentavalent antimonials remain the cornerstone of treatment, underscoring the need for better therapeutic options.